How did erenumab's approval by the FDA change the landscape of migraine treatment?
“The future of the prevention of migraine is very bright.”
Peter J. Goadsby, MD, PhD, DSc, a professor of neurology at both the University of California San Francisco and King’s College, London, as well as the director of the NIHR-Wellcome Trust Clinical Research Facility at King’s College Hospital and the Chair of the British Association for the Study of Headache, sat with NeurologyLive to provide some insight about the landscape of migraine prevention in a post-erenumab approval world.
After the FDA green lit erenumab (Aimovig, Amgen/Novartis), the hope surrounding the remaining players in the class of calcitonin gene-related peptide (CGRP) inhibitors skyrocketed—though with some cautious optimism. Goadsby spoke about how the approval established that the research into migraine has worked and that the field is headed in the right direction.
The headache specialist also spoke about the future of migraine prevention, and what sort of synergistic relationships that could develop between the CGRP class of medicines and the other pathways being explored, such as the pituitary adenylate cyclase-activating polypeptide (PACAP) pathway, or the small molecule gepants that are being explored.